Philips (PHG) Q3 2026 earnings review
Philips scanner orders jump 8%, but factory delays stall deliveries
Hospital equipment orders at Philips, the Dutch maker of hospital scanners and Sonicare toothbrushes, rebounded while factory delays held back ultrasound deliveries. Underlying sales rose 3%, as consumer products and patient monitors made up for flat scanner revenue. Operating margin excluding one-offs expanded 0.7 percentage points to 13% instead of falling as finance chief Charlotte Hanneman had warned, while a EUR 288 million US Justice Department settlement charge cut reported profit.
| Sales from businesses owned a year ago | +3% EUR 4.39B reported (+2% from a year ago) |
|---|---|
| Comparable equipment order intake | +8% −1% last quarter and +8% a year ago |
| Operating margin, excluding one-offs | 13.0% +0.7 percentage points from a year ago |
| Full-year 2026 outlook | Unchanged 3–4.5% underlying sales growth; 13.5–14.0% margin |
⚖️ Verdict: 🟢 Bullish
The story got better because an 8% jump in equipment orders and a cleaner operating margin answered the two biggest doubts from last quarter. Chief executive Roy Jakobs kept the full-year outlook unchanged, and the third-quarter profit beat lowers the fourth-quarter margin needed to hit the annual target to just under 16% by our math. Two cautions remain: internal factory changes forced a cut to the imaging division's full-year sales target, and state probes into the Respironics recall stay open.
The question now is whether nearly 20% order growth in the scanner division turns into delivered sales in the fourth quarter or gets stuck behind ultrasound factory bottlenecks and Chinese state price cuts. If factory output recovers on schedule, imaging revenue will accelerate into 2027; if delays persist, consumer toothbrushes and shavers must keep carrying the group. Fourth-quarter scanner deliveries will settle it.
🐂 Bull Case
Scanner Orders Rebounded Nearly 20% After Last Quarter's Dip
Hospital equipment orders drive future revenue at Philips, but they fell 1% last quarter. Management blamed order timing and promised a return to mid-single-digit growth. In the third quarter, comparable order intake rose 8% on top of an 8% gain a year earlier. Demand in Diagnosis & Treatment, the unit that sells imaging scanners and surgical suite gear, approached 20% growth, led by hospitals in North America and Europe.
- CT 5300, an artificial-intelligence scanner for routine hospital work: order book nearly doubled from a year ago
- Spectral CT, higher-priced scanners for detailed tissue imaging: order book grew double digits
- BlueSeal, magnetic resonance scanners that run without liquid helium: about 75% of systems shipped this year
Chief executive Roy Jakobs said Philips reached a "turning point in rebuilding the Precision Diagnosis order book, which has now expanded for 3 consecutive quarters". Earlier orders only replaced lost Chinese business, so they did not lift revenue. Now the backlog is full enough that new bookings should add directly to sales.
What to watch: Diagnosis & Treatment sales growth in the fourth quarter. A move back into positive growth will prove that the larger backlog is turning into delivered machines.
Cost Cuts and Patient Monitors Lifted Operating Margin Above Plan
Three months ago, finance chief Charlotte Hanneman warned that rising component costs would push the third-quarter operating profit margin below last year's 12.3%. Instead, the adjusted EBITA margin — operating profit before restructuring and amortisation — rose 0.7 percentage points to 13.0%. All three operating divisions expanded their margins, which lowers the profit jump Philips needs in the fourth quarter to meet its full-year target.
- Cost cuts and pricing: added 2.2 percentage points to the group margin, with EUR 170 million saved in the quarter
- Sales volume, product mix and new products: added 0.5 percentage points
- Component inflation and tariffs: took away 1.8 percentage points, while currency took away 0.3 points
- Connected Care margin: rose 1.9 percentage points to 13.3%, or 3.4 points excluding a one-off investment gain last year
Connected Care led the improvement because hospitals installed more high-margin IntelliVue patient monitors, while Enterprise Informatics, the hospital software unit, grew high-single digits on large project rollouts. By our math, the full-year underlying target still requires a fourth-quarter margin near 15.9%, down from the 16% to 17% hurdle before this beat.
What to watch: fourth-quarter adjusted EBITA margin. Landing at or above 15.5% will confirm that cost savings and seasonal volume can cover rising component prices.
Personal Care Volume Growth Prompted a Segment Target Raise
Personal Health, the consumer division that makes Sonicare electric toothbrushes, OneBlade shavers and Avent baby bottles, has carried top-line growth for Philips all year. Management previously expected the division's growth to slow in the second half against tougher comparisons. Instead, sales from businesses owned a year ago rose 8% in the third quarter on top of an 11% jump last year.
Jakobs said prices were roughly flat, so the 8% gain came from selling more units and winning shelf space at major retailers with new premium products like the Lumea 9900 Pro hair remover. Segment operating margin rose 0.6 percentage points to 17.7% even as the group spent more on advertising. Hanneman raised the division's full-year sales outlook from the upper end of the 3% to 4.5% range to the lower end of high-single digits.
What to watch: holiday sell-out trends in Personal Health during the fourth quarter. Holding growth near 7% or 8% will show that shoppers are still buying higher-priced shavers and toothbrushes.
🐻 Bear Case
Factory Delays in Ultrasound Forced a Segment Target Cut
Diagnosis & Treatment generates nearly half of group revenue, so Philips needs the division to convert its growing order backlog into deliveries. Instead, the division's underlying sales were flat in the third quarter, down from 2% growth in the first half. Mid-single-digit growth in Image-Guided Therapy, which sells Azurion surgical imaging suites, merely offset a mid-single-digit drop in Precision Diagnosis.
Lower Chinese demand was expected, but Hanneman disclosed a new internal bottleneck: in ultrasound, "shipment delays related to manufacturing process improvement weighed on sales". Because factory changes held back shipments longer than planned, Hanneman cut the division's full-year comparable sales target from the lower end of the 3% to 4.5% range to the upper end of low-single digits. Production began ramping up in late September, and some delayed shipments will spill into early 2027.
What to watch: fourth-quarter comparable sales in Diagnosis & Treatment. To hit the lowered full-year target of roughly 2.5% to 3%, fourth-quarter segment sales must accelerate to at least 6% by our math.
Hospital Monitor Orders Slipped for a Second Straight Quarter
When group orders fell 1% in the second quarter, management blamed large North American patient-monitoring deals that slipped into July. Hanneman confirmed that Philips booked those delayed deals early in the third quarter and said she had no concerns about the monitoring unit. Yet Connected Care order intake still fell by a mid-single-digit percentage in the third quarter against a 20%-plus comparison a year ago.
The drop happened because "longer negotiation and contracting cycles for some major enterprise-wide standardization agreements resulted in several other orders shifting into Q4 as well", Jakobs said. Hospitals are bundling hardware with software and subscription services, which stretches out sign-offs. Meanwhile, Philips again showed only an unlabelled bar chart for its total equipment order book rather than giving a euro figure or growth rate.
What to watch: Connected Care order intake in the fourth quarter. A second straight decline would show that hospital IT reviews are slowing deal closures more permanently than a one-quarter delay.
US Justice Department Deal Costs EUR 288 Million, and State Probes Remain
Philips has spent years cleaning up the recall of millions of Respironics sleep-apnoea and breathing machines. In the third quarter, the Dutch medical device maker reached an agreement in principle with the US Department of Justice "to resolve the previously disclosed criminal and civil investigations related to the Respironics recall". Simultaneously, a Dutch court rejected investor requests for a probe into how management handled the recall.
To pay for the US federal deal, Philips took a EUR 288 million charge in the third quarter, which pushed Connected Care into a EUR 195 million operating loss and cut group operating profit to EUR 165 million. The cash leaves in the first quarter of 2027. However, the settlement does not let Respironics resume selling sleep machines in the US under its Food and Drug Administration consent decree, and the outlook still excludes other legal actions, "including the investigation by the US State Attorneys General".
What to watch: final documentation of the Justice Department settlement and any reserve for the 41 US State Attorneys General. Another multi-hundred-million-euro bill would eat into 2027 cash generation.
👓 Other Themes
China State Buying Keeps Hospital Sales Flat Despite an Order Bounce
Chinese hospital orders grew in the third quarter, helped by government equipment-renewal timing and an easy comparison from a year ago. Even so, Jakobs kept a cautious view because "centralized procurement continues to expand" across China, which forces medical device makers to bid lower prices to win state tenders. Philips still expects full-year Chinese revenue to stay roughly flat, with consumer sales offsetting lower hospital equipment revenue.
💲 Other KPIs
Free cash flow more than doubled from EUR 172 million a year ago, helped by higher cash profit and smaller working-capital outflows. That cash generation pushed net debt down to EUR 5.4 billion, or 1.7 times annual operating profit before depreciation, down from 2.2 times a year earlier and inside management's 1.5 to 2.0 target band.
Inventory rose for a third straight quarter as a share of trailing 12-month sales, up from 16.1% at year-end, 18.2% last quarter and 18.3% a year ago. Hanneman said Philips stocked up ahead of the fourth-quarter holiday rush in Personal Health and bought electronic parts early to beat rising component prices.
Diluted profit per share excluding one-offs rose 11.1% from EUR 0.36 a year ago, driven by higher operating profit and lower net interest costs of EUR 42 million versus EUR 57 million last year. That marks a return to clean growth after an 8% drop in the first quarter and a tariff-refund-boosted EUR 0.49 in the second.
🔮 Guidance
Unchanged. The group plan still calls for 3% to 4.5% growth from businesses owned a year ago, after 3.5% in the first nine months. By our math, the middle of the range (3.75%) requires about 4.4% growth in the fourth quarter, up from 3.0% this quarter. Inside the total, Philips raised Personal Health to the lower end of high-single digits and cut Diagnosis & Treatment to the upper end of low-single digits.
Unchanged. The full-year target includes roughly 1 percentage point from the EUR 186 million US customs refund booked in the second quarter. Excluding that refund, the nine-month margin stands at 11.5%, up 0.3 points from a year ago. By our math, reaching the 12.75% underlying midpoint leaves a 15.9% margin for the fourth quarter, compared with 15.1% in the fourth quarter of 2025.
Unchanged. The cash target includes a net EUR 200 million benefit from the US tariff refund and assumes Philips pays the EUR 288 million Justice Department settlement in the first quarter of 2027. With EUR 634 million generated in the first nine months, the EUR 1.6 billion middle of the range leaves EUR 966 million for the fourth quarter by our math, down 19.5% from EUR 1.2 billion a year ago.
Raised for the legal settlement. One-off charges outside restructuring moved from roughly 1.2 percentage points of annual sales to 2.8 points solely to reflect the EUR 288 million Respironics Justice Department provision booked this quarter. Excluding that settlement, full-year one-off items stay at 1.8 points of sales, with EUR 170 million of charges planned for the fourth quarter.
Improved. Philips lowered its expected full-year net interest and financial expense by EUR 20 million from the middle of the old range after third-quarter net financial costs fell to EUR 42 million on higher interest income and fair-value gains. It is the second trim this year, down from EUR 250 million to EUR 270 million in the first quarter.
Raised on sales, lowered on unadjusted profit. Philips lifted expected Segment Other revenue by EUR 35 million at the middle of the range because of transitional services tied to divested businesses, which add about EUR 170 million for the year and EUR 50 million in the fourth quarter. Unadjusted segment loss widened by EUR 50 million to roughly EUR 120 million, with EUR 80 million of one-off charges set for the fourth quarter.
❓ Key Questions
How large is the ultrasound shipment backlog moving into 2027?
Factory process changes held back third-quarter ultrasound deliveries and forced a cut to the full-year Diagnosis & Treatment sales target. Investors need the euro value of delayed shipments and how much spills into 2027 rather than closing in the fourth quarter.
What is the euro value of the equipment order book?
Philips reported 8% order growth and said its Precision Diagnosis backlog reached a turning point, yet it showed only an unlabelled bar chart for the total order book. Without a euro figure or book-to-bill ratio, outsiders cannot verify how fast orders will lift sales.
How much revenue shifted in the delayed hospital monitoring deals?
For a second straight quarter, management cited longer contracting cycles for large hospital-standardisation deals moving Connected Care orders into the next quarter. Quantifying the slipped bookings would show whether hospital IT budgets are tightening or merely taking longer to sign.
What exposure remains to the 41 US State Attorneys General?
The EUR 288 million US Department of Justice settlement resolves federal civil and criminal probes into the Respironics recall, but the outlook still excludes state investigations. Any estimate of the timeline or legal reserve is critical for judging 2027 free cash flow.